Genmab's Rina-S shows 45.9% response rate in ovarian cancer trial
Tweet Send to a Friend
Genmab A/S (Nasdaq: GMAB) reported Phase 2 results from Part C of its RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S), an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




